GlassScriptPhysician profile
Melissa A Studebaker
NPI 1821230855
$16,259.23
in general payments reported to CMS, 2019-2025
63 companies · $2,555 in 2025
The $2,555 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,457 · 2022: $3,272 · 2023: $3,245 · 2024: $2,731 · 2025: $2,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,687 · Education: $677 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,687.14 |
| Education | $676.56 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,407.66 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,438.61 | 2021-2025 | Enhertu, Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $1,029.92 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $1,000.17 | 2021-2025 | |
| Astellas Pharma US INC | $670.16 | 2021-2025 | Vyloy, Padcev, Xospata |
| Seagen INC. | $669.18 | 2021-2024 | Adcetris, Padcev |
| Janssen Biotech, INC. | $595.62 | 2021-2025 | Darzalex, Tecvayli, Erleada |
| Amgen INC. | $554.70 | 2021-2023 | Kyprolis, Xgeva, Vectibix |
| E.R. Squibb & Sons, L.L.C. | $495.57 | 2021-2025 | Opdivo, Reblozyl |
| Incyte Corporation | $491.84 | 2021-2025 | Jakafi |
| Celgene Corporation | $393.38 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Regeneron Healthcare Solutions, INC. | $393.10 | 2021-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $391.63 | 2021-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Daiichi Sankyo INC. | $390.55 | 2021-2025 | Injectafer, Enhertu |
| Genzyme Corporation | $379.45 | 2021-2025 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $330.00 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $281.46 | 2021-2024 | Polivy, Gazyva, Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $277.31 | 2021-2025 | |
| Eisai INC. | $269.42 | 2021-2024 | |
| Pharmacosmos Therapeutics INC. | $257.97 | 2022-2025 | Monoferric, Cosela |
| Puma Biotechnology, INC. | $242.39 | 2021-2025 | |
| Abbvie INC. | $230.07 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $212.87 | 2021-2025 | |
| Beigene USA, INC. | $211.89 | 2022-2024 | Brukinsa |
| Taiho Oncology, INC. | $206.80 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $189.10 | 2021-2025 | Xpovio |
| Gilead Sciences, INC. | $176.76 | 2022-2025 | Trodelvy |
| Stemline Therapeutics INC. | $174.28 | 2023-2025 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.41 | 2021-2022 | |
| Adaptive Biotechnologies Corporation | $166.02 | 2023-2024 | Clonoseq |
| Glaxosmithkline, LLC. | $139.68 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Pharmacyclics LLC, An Abbvie Company | $122.72 | 2021-2023 | Imbruvica |
| Sobi, INC | $112.38 | 2022-2024 | |
| Array Biopharma INC | $106.17 | 2021-2024 | Braftovi, Lorbrena, Mektovi |
| Servier Pharmaceuticals LLC | $99.62 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $81.84 | 2021-2024 | Onivyde |
| Beone Medicines USA, INC. | $80.27 | 2025 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $75.36 | 2021-2024 | Qinlock |
| Epizyme, INC. | $64.85 | 2021-2022 | |
| Mirati Therapeutics, INC. | $53.55 | 2024 | Krazati |
| Emd Serono, INC. | $43.09 | 2021-2022 | |
| G1 Therapeutics, INC. | $42.75 | 2022-2023 | Cosela |
| Legend Biotech USA INC. | $42.72 | 2024 | |
| Aveo Pharmaceuticals, INC. | $36.88 | 2023-2024 | Fotivda |
| Ge Healthcare | $33.62 | 2022 | |
| Cti Biopharma Corp. | $32.51 | 2023 | Vonjo |
| Morphosys, US INC. | $30.87 | 2021-2022 | |
| Tersera Therapeutics LLC | $29.73 | 2023 | Zoladex |
| Pharmaessentia USA Corporation | $28.73 | 2024 | Besremi |
| Amag Pharmaceuticals, INC. | $28.18 | 2021 | |
| Genmab U.S., INC. | $27.04 | 2024 | Epkinly |
| Alnylam Pharmaceuticals INC. | $26.50 | 2022 | |
| Recordati_rare_diseases_inc. | $24.99 | 2025 | Enjaymo |
| Caris Mpi, INC. | $24.72 | 2025 | Mi Cancer Seek |
| Syndax Pharmaceuticals, INC. | $21.79 | 2025 | |
| Tg Therapeutics, INC. | $20.40 | 2021 | |
| Geron Corporation | $20.25 | 2025 | Rytelo |
| Foundation Medicine, INC. | $20.19 | 2022 | |
| Csl Behring | $20.13 | 2021 | |
| Adc Therapeutics America, INC. | $19.31 | 2023 | |
| Sumitomo Pharma America, INC. | $19.18 | 2023 | Orgovyx |
| Global Blood Therapeutics, INC. | $17.78 | 2022 | |
| Dova Pharmaceuticals | $14.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Studebaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.